Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 410

Sort by

Sort Order Select

Journal Articles

Mutant ASXL1 Promotes Expansion of the Phenotypic Hematopoietic Stem Cell Compartment

Takeshi Fujino, MD, Susumu Goyama, MD PhD, Yuki Sugiura, PhD, Daichi Inoue, MD PhD, Satoshi Yamasaki, PhD, Akiko Matsumoto, Naru Sato, MD, Hironobu Morinaga, PhD, Shiori Shikata, Tomofusa Fukuyama, MD PhD, Yosuke Tanaka, PhD, Shuhei Asada, MD PhD, Tsuyoshi Fukushima, MD PhD, Hiroaki Honda, MD PhD, Emi K Nishimura, MD PhD, Tatsuhiro Shibata, MD PhD, Makoto Suematsu, MD PhD, Toshio Kitamura, MD PhD

Blood (2019) 134 (Supplement_1): 821.

https://doi.org/10.1182/blood-2019-127904

Published: 2019

Journal Articles

Deletion of CISH in Human Pluripotent Stem Cell-Derived Natural Killer Cells Enhances Anti-Tumor Activity Via Metabolic Reprogramming

Huang Zhu, PhD, Robert Blum, Zhengming Wu, Zhipeng Meng, PhD, Kun-Liang Guan, PhD, Dan S Kaufman, MD PhD

Blood (2019) 134 (Supplement_1): 619.

https://doi.org/10.1182/blood-2019-124446

Published: 2019

Journal Articles

Role of Autophagy in Resistance of FLT3-ITD AML Stem Cells to FLT3 TKI Treatment

Shaowei Qiu, MD, Chengcheng Yan, MD, Andrew J Paterson, PhD, Hui Li, BS, Nick Anderson, BS, Ajay Abraham, PhD, Jianbo He, MD, Mansi Shah, PhD, Puneet Agarwal, Jing Yang, PhD, Min Xie, MD, Rui Lu, PhD, Rob S. Welner, PhD, Ravi Bhatia, MD

Blood (2019) 134 (Supplement_1): 2548.

https://doi.org/10.1182/blood-2019-124948

Published: 2019

Journal Articles

CK2 Inhibitor CX4945 Shows Strong In Vivo Synergistic Anti-Leukemia Activity with Rapamycin in B-ALL Due to Enhanced Ikaros Mediated Repression of mTOR Pathway

Chandrika Gowda, MBBS, Chunhua Song, MD, Yali Ding, PhD, Pavan kumar Dhanyamraju, PhD, Soumya Iyer, PhD, Jonathon Payne, Yevgeniya Bamme, MD, Arati Sharma, PhD, Kimberly J. Payne, PhD, Sinisa Dovat, MD PhD

Blood (2019) 134 (Supplement_1): 2634.

https://doi.org/10.1182/blood-2019-131790

Published: 2019

Journal Articles

Quantitative Investigation of Pharmacologically Modulated Signaling and Efficacy in ABC DLBCL Using a Systems Pharmacology Model

Kosinsky Yuri, PhD, Lulu Chu, PhD, Millie Shah, PhD, Karthick Vishwanathan, PhD, Connie Larsson, PhD, Andrew Bloecher, PhD, Brandon Willis, PhD, Hannah Dry, BSc, Kirill Peskov, PhD, Joseph Ware, PhD, Andrew Mortlock, PhD, Gabriel Helmlinger, PhD

Blood (2019) 134 (Supplement_1): 5304.

https://doi.org/10.1182/blood-2019-130879

Published: 2019

Journal Articles

Associations between Microrna Expression, Disease Progression and Ex Vivo Drug Response in Multiple Myeloma

Romika Kumari, PhD, Ashwini Kumar, MRes, Alun Parsons, Minna Suvela, MSC, Juha Lievonen, MD, Raija Helena Silvennoinen, MD PhD, Pekka Anttila, MD, Caroline A Heckman, PhD

Blood (2019) 134 (Supplement_1): 3069.

https://doi.org/10.1182/blood-2019-128181

Published: 2019

Journal Articles

Inhibition of PIM Kinases Targets Synthetic Vulnerabilities and Enhances Antigen Presentation in B-Cell Lymphoma

Patrizia Mondello, MD PhD MSc, Chiara Tarantelli, PhD, Luciano Cascione, PhD, Alberto Arribas, PhD, Andrea Rinaldi, Anas Younes, MD, Francesco Bertoni, MD

Blood (2019) 134 (Supplement_1): 2858.

https://doi.org/10.1182/blood-2019-125123

Published: 2019

Journal Articles

Study Design of an Open-Label, Single-Arm, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Defibrotide in Adult Patients with Transplant-Associated Thrombotic Microangiopathy

Vincent T. Ho, Nino Keshelava, Suzanne Swann, William Tappe

Blood (2019) 134 (Supplement_1): 3257.

https://doi.org/10.1182/blood-2019-123520

Published: 2019

Journal Articles

Acquired Dysfibrinogenemia Krakow III after Everolimus Therapy

Alona A. Merkulova, MA, Steven C. Mitchell, MA, Sergei Merkulov, PhD, Alisa S. Wolberg, PhD, Neerman-Arbez Marguerite, PhD, Alvin H. Schmaier, MD

Blood (2019) 134 (Supplement_1): 4934.

https://doi.org/10.1182/blood-2019-131319

Published: 2019

Journal Articles

mTOR Signal Pathway Inhibition Promote the Cytotoxicity of Chemotherapy on SHI-1 Cells

Jing Xu, Zhenjiang Li, Jifu Zheng, Qiong Wu, Qingming Wang, Aiping Tang, Yuan Song, Yan Fei

Blood (2019) 134 (Supplement_1): 5126.

https://doi.org/10.1182/blood-2019-126714

Published: 2019

Journal Articles

Class I PI3K Is Required for HSC Differentiation

Kristina Ames, PhD, Imit Kaur, PhD, Meng Tong, Shayda Hemmati, PhD, Ellen Tein, Shira Glushakow-Smith, Lindsay Gurska, Kira Gritsman, MD PhD

Blood (2019) 134 (Supplement_1): 2461.

https://doi.org/10.1182/blood-2019-123823

Published: 2019

Journal Articles

Whole-Genome CRISPR Screen Reveals the Mechanism of Relapse in Patient-Derived Cells Representing High-Risk Paediatric ALL

Katarzyna Szoltysek, PhD, Helen Blair, Sirintra Nakjang, Ricky Tirtakusuma, Mankaran Singh, Ryan Nelson, Hesta McNeill, Catherine Dodd, Melanie Beckett, Lynsey McKenzie, Edward Law, Josef Vormoor, MD PhD, Deepali Pal, Olaf Heidenreich

Blood (2019) 134 (Supplement_1): 3952.

https://doi.org/10.1182/blood-2019-124818

Published: 2019

Journal Articles

Novel Mechanisms for Resistance to Targeted Therapy Identified through Machine Learning Approaches in 1167 RNA-Seq Drug Exposure Profiles in Lymphoma

Nicholas Davis, PhD, Matthew S. McKinney, MD, Anupama Reddy, PhD, Cassandra Love, Eileen Smith, Lanie Happ, Sandeep Dave, MD

Blood (2018) 132 (Supplement 1): 1370.

https://doi.org/10.1182/blood-2018-99-119639

Published: 2018

Journal Articles

Pi3k/Akt/Mtor Pathway Activity Is Increased in Lymph Node Tissue from Idiopathic Multicentric Castleman Disease Patients with Tafro Syndrome

Dustin Shilling, PhD, Dale M Kobrin, BA, David C Fajgenbaum, MD MBA, MSc

Blood (2018) 132 (Supplement 1): 1121.

https://doi.org/10.1182/blood-2018-99-118434

Published: 2018

Journal Articles

Targeting Intracellular Signaling Cascades for Patients with Relapsed, Refractory Multiple Myeloma: A Systematic Review of Clinical Trials

Shehroz Aslam, MD, Mustafa Nadeem Malik, MD, Abdul Rafae, MD, Rida Riaz, MBBS, Seren Durer, MD, Ceren Durer, MD, Faisal Mahfooz, MD, Muhammad Jahanzeb Khalil, MD, Jemin Aby Jose, MD, Zunairah Shah, MBBS, Chaudhry Saad Sohail, MD, Maaz Ahmed Yusufi, MD, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 5659.

https://doi.org/10.1182/blood-2018-99-115721

Published: 2018

Journal Articles

Beyond JAK2 Inhibitors: A Systematic Review of Management Strategies for Myelofibrosis

Ali Younas Khan, MD, Nimra Iftikhar, MD, Awais Ijaz, MD, Muhammad Junaid Tariq, MD, Faiza Jamil, MD, Arshia Akbar, MD, Anum Qureshi, Jemin Aby Jose, MD, Ahmad Kamal, MD, Muhammad Abu Zar, MD, Madeeha Shafqat, Insija Ilyas Selene, MBBS, Shehroz Aslam, MD, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 5484.

https://doi.org/10.1182/blood-2018-99-115867

Published: 2018

Journal Articles

RUNX1 Mutations Identify an Entity of Blast Phase Chronic Myeloid Leukemia (BP-CML) Patients with Distinct Phenotype, Transcriptional Profile and Drug Vulnerabilities

Shady Awad, MD, Matti Kankainen, PhD, Olli Dufva, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Satu Mustjoki, MD PhD

Blood (2018) 132 (Supplement 1): 4257.

https://doi.org/10.1182/blood-2018-99-111602

Published: 2018

Journal Articles

New Molecular and Therapeutic Insights into Canine Diffuse Large B Cell Lymphoma Elucidates the Role of the Dog As a Model for Human Disease

Blood (2018) 132 (Supplement 1): 4173.

https://doi.org/10.1182/blood-2018-99-112763

Published: 2018

Journal Articles

Omipalisib (GSK458), a Dual an-PI3K/mTOR Inhibitor, Exhibits in Vitro and In Vivo activity in Chemotherapy-Sensitive and -Resistant Models of Burkitt Lymphoma

Thomas Ippolito, MSc, Cory Mavis, BSc, MSc, Juan Gu, MD PhD, Francisco J. Hernandez-Ilizaliturri, MD, Matthew J. Barth, MD

Blood (2018) 132 (Supplement 1): 2951.

https://doi.org/10.1182/blood-2018-99-119048

Published: 2018

Journal Articles

Management of Cytopenias in CTLA4 Haploinsufficiency Using Abatacept and Sirolimus

Gulbu Uzel, MD, Djuro Karanovic, MD, Hua Su, PhD, Amy Rump, Anahita Agharahimi, Steven M. Holland, MD, V. Koneti Rao, MD FRCPA

Blood (2018) 132 (Supplement 1): 2409.

https://doi.org/10.1182/blood-2018-99-120185

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Mutant ASXL1 Promotes Expansion of the Phenotypic Hematopoietic Stem Cell Compartment

Deletion of CISH in Human Pluripotent Stem Cell-Derived Natural Killer Cells Enhances Anti-Tumor Activity Via Metabolic Reprogramming

Role of Autophagy in Resistance of FLT3-ITD AML Stem Cells to FLT3 TKI Treatment

CK2 Inhibitor CX4945 Shows Strong In Vivo Synergistic Anti-Leukemia Activity with Rapamycin in B-ALL Due to Enhanced Ikaros Mediated Repression of mTOR Pathway

Quantitative Investigation of Pharmacologically Modulated Signaling and Efficacy in ABC DLBCL Using a Systems Pharmacology Model

Associations between Microrna Expression, Disease Progression and Ex Vivo Drug Response in Multiple Myeloma

Inhibition of PIM Kinases Targets Synthetic Vulnerabilities and Enhances Antigen Presentation in B-Cell Lymphoma

Study Design of an Open-Label, Single-Arm, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Defibrotide in Adult Patients with Transplant-Associated Thrombotic Microangiopathy

Acquired Dysfibrinogenemia Krakow III after Everolimus Therapy

mTOR Signal Pathway Inhibition Promote the Cytotoxicity of Chemotherapy on SHI-1 Cells

Class I PI3K Is Required for HSC Differentiation

Whole-Genome CRISPR Screen Reveals the Mechanism of Relapse in Patient-Derived Cells Representing High-Risk Paediatric ALL

Novel Mechanisms for Resistance to Targeted Therapy Identified through Machine Learning Approaches in 1167 RNA-Seq Drug Exposure Profiles in Lymphoma

Pi3k/Akt/Mtor Pathway Activity Is Increased in Lymph Node Tissue from Idiopathic Multicentric Castleman Disease Patients with Tafro Syndrome

Targeting Intracellular Signaling Cascades for Patients with Relapsed, Refractory Multiple Myeloma: A Systematic Review of Clinical Trials

Beyond JAK2 Inhibitors: A Systematic Review of Management Strategies for Myelofibrosis

RUNX1 Mutations Identify an Entity of Blast Phase Chronic Myeloid Leukemia (BP-CML) Patients with Distinct Phenotype, Transcriptional Profile and Drug Vulnerabilities

New Molecular and Therapeutic Insights into Canine Diffuse Large B Cell Lymphoma Elucidates the Role of the Dog As a Model for Human Disease

Omipalisib (GSK458), a Dual an-PI3K/mTOR Inhibitor, Exhibits in Vitro and In Vivo activity in Chemotherapy-Sensitive and -Resistant Models of Burkitt Lymphoma

Management of Cytopenias in CTLA4 Haploinsufficiency Using Abatacept and Sirolimus

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only